Best step-up treatments for children with uncontrolled asthma: a systematic review and network meta-analysis of individual participant data

医学 哮喘 荟萃分析 安慰剂 系统回顾 临床试验 恶化 心理干预 梅德林 物理疗法 内科学 儿科 替代医学 护理部 法学 病理 政治学
作者
Sofia Cividini,Ian Sinha,Sarah Donegan,Michelle Maden,Katie Rose,Olivia Fulton,Giovanna Culeddu,Dyfrig Hughes,Steve Turner,Catrin Tudur Smith
出处
期刊:The European respiratory journal [European Respiratory Society]
卷期号:62 (6): 2301011-2301011 被引量:1
标识
DOI:10.1183/13993003.01011-2023
摘要

Background There is uncertainty about the best treatment option for children/adolescents with uncontrolled asthma despite inhaled corticosteroids (ICS) and international guidelines make different recommendations. We evaluated the pharmacological treatments to reduce asthma exacerbations and symptoms in uncontrolled patients age <18 years on ICS. Methods We searched MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Embase, Web of Science, National Institute for Health and Care Excellence Technology Appraisals, National Institute for Health and Care Research Health Technology Assessment series, World Health Organization International Clinical Trials Registry, conference abstracts and internal clinical trial registers (1 July 2014 to 5 May 2023) for randomised controlled trials of participants age <18 years with uncontrolled asthma on any ICS dose alone at screening. Studies before July 2014 were retrieved from previous systematic reviews/contact with authors. Patients had to be randomised to any dose of ICS alone or combined with long-acting β 2 -agonists (LABA) or combined with leukotriene receptor antagonists (LTRA), LTRA alone, theophylline or placebo. Primary outcomes were exacerbation and asthma control. The interventions evaluated were ICS (low/medium/high dose), ICS+LABA, ICS+LTRA, LTRA alone, theophylline and placebo. Results Of the 4708 publications identified, 144 trials were eligible. Individual participant data were obtained from 29 trials and aggregate data were obtained from 19 trials. Compared with ICS Low, ICS Medium+LABA was associated with the lowest odds of exacerbation (OR 0.44, 95% credibility interval (95% CrI) 0.19–0.90) and with an increased forced expiratory volume in 1 s (mean difference 0.71, 95% CrI 0.35–1.06). Treatment with LTRA was the least preferred. No apparent differences were found for asthma control. Conclusions Uncontrolled children/adolescents on low-dose ICS should be recommended a change to medium-dose ICS+LABA to reduce the risk for exacerbation and improve lung function.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
紫曦完成签到,获得积分10
1秒前
温婉的凝芙完成签到 ,获得积分10
2秒前
2秒前
bewilderment完成签到,获得积分10
2秒前
笑林完成签到 ,获得积分0
3秒前
王子语完成签到,获得积分10
3秒前
霸气若之完成签到,获得积分10
3秒前
刘威完成签到,获得积分10
3秒前
4秒前
cxc完成签到,获得积分20
4秒前
小贝完成签到,获得积分10
5秒前
liu完成签到,获得积分10
5秒前
《子非鱼》完成签到,获得积分10
6秒前
顽童完成签到 ,获得积分10
7秒前
7秒前
whuhustwit完成签到,获得积分10
7秒前
meng完成签到,获得积分10
8秒前
NexusExplorer的应助被顾志成采纳,获得10
9秒前
9秒前
vampv完成签到,获得积分0
9秒前
Crazy_Runner发布了新的文献求助10
9秒前
10秒前
可爱的微笑完成签到 ,获得积分10
10秒前
可爱的微笑完成签到 ,获得积分10
10秒前
可爱的微笑完成签到 ,获得积分10
10秒前
David发布了新的文献求助30
10秒前
11秒前
自由的白开水完成签到,获得积分10
11秒前
12秒前
瞿伟伟完成签到,获得积分10
12秒前
搞怪的白竹完成签到,获得积分10
12秒前
杨思悦完成签到 ,获得积分10
12秒前
陈熙乐完成签到 ,获得积分10
13秒前
13秒前
怡然涫完成签到 ,获得积分10
14秒前
濮阳盼曼完成签到,获得积分0
14秒前
闫玉坤完成签到,获得积分10
14秒前
科研通AI6.4的应助被CarryLJR采纳,获得10
15秒前
流星完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159151
求助须知:如何正确求助?哪些是违规求助? 9554617
关于积分的说明 21719982
捐赠科研通 7748814
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552091
邀请新用户注册赠送积分活动 2471436